Galera Therapeutics, Inc.

NasdaqGM:GRTX Stock Report

Market Cap: US$11.3m

Galera Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Galera Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth21.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Feb 15
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Oct 25
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics appoints chief medical officer

Sep 01

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Jun 29

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Jun 15
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Mar 23

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 24
Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Dec 24

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Nov 04
Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Aug 05
Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 17
Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics EPS beats by $0.08

Nov 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Galera Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqGM:GRTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2023N/A-59-45-45N/A
9/30/2023N/A-70-49-49N/A
6/30/2023N/A-71-46-46N/A
3/31/2023N/A-64-44-44N/A
12/31/2022N/A-62-43-43N/A
9/30/2022N/A-63-47-47N/A
6/30/2022N/A-69-56-56N/A
3/31/2022N/A-77-64-64N/A
12/31/2021N/A-81-68-68N/A
9/30/2021N/A-84-67-67N/A
6/30/2021N/A-78-64-64N/A
3/31/2021N/A-75-63-62N/A
12/31/2020N/A-74-60-60N/A
9/30/2020N/A-72-59-58N/A
6/30/2020N/A-70-57-56N/A
3/31/2020N/A-65-50-50N/A
12/31/2019N/A-59-47-47N/A
9/30/2019N/A-52-39-38N/A
6/30/2019N/A-43-31-30N/A
3/31/2019N/A-36-26-26N/A
12/31/2018N/A-30-23-22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if GRTX's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if GRTX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if GRTX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if GRTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GRTX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GRTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.